Oral cannabinoid pharmaceutical compositions and methods of treating sleep disorders

An oral pulse-release dosage form, comprising a total daily dose of a first cannabinoid active pharmaceutical ingredient (API1) and a total daily dose of a second cannabinoid API (API2), wherein the pulse-release dosage form comprises:

• a first pulse-release component (C1) comprising a first portion (P1) of the first cannabinoid API (API1P1) and a first portion (P1) of the second cannabinoid API (API2P1);
• a second pulse-release component (C2) comprising a second portion (P2) of the first cannabinoid API (API1P2) and a second portion (P2) of the second cannabinoid API (API2P2);
• and
• at least a third pulse-release component (C3) comprising a third portion (P3) of the first cannabinoid API (API1P3) and a third portion (P3) of the second cannabinoid API (API2P2);
• wherein the total daily dose of each of the API1 and the API2 is divided between the first portion (P1) in the first pulse-release component (C1), the second portion (P2) in the second pulse-release component (C2), and at least the third portion (P3) in the at least third pulse-release component (C3);
• and
• wherein when the pulse-release dosage form is placed in an aqueous solution of 0.1N HCl pH 1.1 for 2 hours followed by 8 hours in sodium phosphate buffer at pH6.8, at 37° C.±0.5° C.,
• the pulse-release dosage form provides release of the API1P2 and the API2P2 beginning from 1 to 4 hours after release of the API1P1 and the API2P1 begins, and release of the API1P3 and the API2P3 beginning from 1 to 4 hours after release of the API1P2 and the API2P2 begins.